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Objective: Boswellic acid is a plant-derived molecule with putative anti-inﬂammatory effects. This study
was performed to determine whether oral or topical administration of boswellic acid can attenuate joint
damage in a mouse model of osteoarthritis (OA).
Methods: Levels of boswellic acid were measured in the blood and synovium of mice treated with oral or
topical boswellic acid. OA was generated by surgical destabilization of the medial meniscus (DMM).
Therapy with oral or topical boswellic acid was initiated one day after surgery and continued for 12
weeks, when knees were harvested and scored histologically for degree of cartilage loss, osteophyte
formation, and synovitis. Microdissected OA synovium was stimulated with IL-1b or lipopolysaccharide
(LPS) in the presence or absence of boswellic acid and cytokine production by quantitative polymerase
chain reaction (PCR) or multiplex enzyme linked immunoabsorbant assay (ELISA).
Results: Topical treatment resulted in synovial concentrations of boswellic acid 2e6-fold higher than
that measured in plasma. Cartilage loss was signiﬁcantly reduced in mice treated with oral or topical
boswellic acid compared with vehicle control (P < 0.01 for both oral and topical therapies). Likewise,
treatment with either oral boswellic acid or boswellic acid ointment reduced of synovitis (P ¼ 0.006 and
0.025, respectively) and osteophyte formation (P ¼ 0.009 and 0.030, respectively). In vitro, boswellic acid
was able to inhibit IL-1b and TLR4 mediated induction of several inﬂammatory mediators from OA sy-
novial explant tissue.
Conclusions: Signiﬁcant synovial concentration and therapeutic efﬁcacy can be achieved with topical
boswellic acid treatment. These ﬁndings suggest that boswellic acid has potential as a disease-modifying
agent in OA.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
80% of the population has radiographic evidence of osteoar-
thritis (OA) by age 65, and over 60% of those have symptoms of OA1.
Current treatments are limited to behavioral interventions, symp-
tomatic medical management, and ultimately, joint replacement
surgery. Therapies with potential to slow or halt disease progres-
sion are urgently needed. Given that OA is a chronic, nonfatal dis-
ease that occurs in an older population with medical and physical: W.H. Robinson, GRECC, VA
SA.
J. Sokolove, GRECC, VA Palo
obinson), sokolove@stanford.
r Ltd on behalf of Osteoarthritis Recomorbidities, such disease-modifying therapies must display a
stringent safety proﬁle.
One approach to improving a drug’s safety proﬁle is to limit
exposure by topical application at or near sites of pathology as has
been demonstrated successfully to limit systemic corticosteroid
exposure using transdermal or inhaled administration. In the
treatment of OA, several agents have been used topically, including
analgesics (e.g., salicylates, capsaicin), and indomethacin2,3.
Boswellia resin, usually derived from the plant Boswellia serrata,
has been used since biblical times as a natural anti-inﬂammatory
therapeutic in traditional Indian Ayurvedic medicine and tradi-
tional Chinese medicine4. Findings from small clinical trials suggest
that oral Boswellia is efﬁcacious in the treatment of both OA5,6 as
well as rheumatoid arthritis (RA) several other inﬂammatory con-
ditions (Reviewed in Ref. 4).
Boswellic acids, especially acetyl-11-keto-b-boswellic acid are
potent inhibitors of 5-lipoxygenase (5-LO), an enzyme that cata-
lyzes the generation of leukotrienes including LTB47; a moleculesearch Society International.
Table I
Boswellic acid levels in synovial tissue and plasma after oral or topical
administration
Boswellic acid 1 h after treatment
Oral
(n ¼ 3 mice)
Ointment
(n ¼ 3 mice)
Cream
(n ¼ 3 mice)
Synovial tissue
level* (ng/g)
854  479 6,462  1,452 1,052  269
Plasma level
(ng/mL)
7,350  3,531 973  320 563  164
* Synovium was microdissected from three mice and independently assayed for
levels of boswellic acid as normalized by weight. Results represent average con-
centration 95% CI.
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boswellic acid can inhibit toll-like receptor (TLR)-mediated acti-
vation of monocytes, suppressing LPS-induced production of nitric
oxide, IL-1b, and TNFa9,10. Finally, derivatives of boswellic acid have
been demonstrated to suppress IL-b induced apoptosis of chon-
drocytes as well as TNFa induced production of MMP3 by synovial
ﬁbroblasts11 thus demonstrating clear therapeutic potential for the
treatment of OA.
To date, there have been few studies of boswellic acid in animal
models of OA and, to our knowledge no study has assessed the
efﬁcacy of topically therapy. In this study, we used a well-
established mouse model of OA to evaluate and compare the
therapeutic efﬁcacy of topical and oral boswellic acid preparations
in treating post-traumatic OA.
Methods
Animals
20-week-old male C57BL/6J mice were purchased from Jackson
Laboratories (Bar Harbor, ME) and treated according to the Guide-
lines for Animal Care of the US National Institutes of Health and
Stanford University. All animal experiments were performed under
protocols approved by the Stanford Committee of Animal Research.
Surgical mouse model of OA
Mouse OAwas generated according to the destabilization of the
medial meniscus (DMM) model, which results in articular cartilage
loss and synovitis similar to that observed in human OA12,13. In the
DMM model, the anterior cruciate ligament (ACL) and medial
meniscotibial ligament (MML) of the mouse are severed under
microscopy, and the mice are sacriﬁced 12 weeks after surgery. We
utilized four groups of eight mice (oral boswellic acid, topical
boswellic acid ointment or cream, or vehicle control ointment). This
experiment was replicated once with 14 mice per group providing
eight mice for histology and allowing an addition six mice for
harvesting of synovial tissue to allow quantitation of boswellic acid
(n ¼ 3) as well as inﬂammatory cytokines (n ¼ 3) in each treatment
group. All animals were housed with other mice in their treatment
groups however, with the exception of orally dosed, mice, handing
was identical between topical treatment and control groups.
Treatment of mouse OA
Starting one day after surgery, we mice were administered
either oral (10 mg/kg) or topical boswellic acid cream or ointment
twice daily for 12 weeks. Control mice received topical treatment
with the formulation ointment base without boswellic acid. For
topical application of boswellic acid, we shaved the right stiﬂe joint
mice and applied approximately 25 ml of cream or ointment to the
joint. Boswellic acid cream and ointment were compounded as
described in Supplemental materials.
Evaluation of tissue and plasma levels of boswellic acid
Plasma was obtained by tail-vein bleeding, and synovial tissue
was microdissected from the stiﬂe joint. Plasma or tissue samples
were precipitated with acetonitrile, and level of beta-boswellic acid
were evaluated by liquid chromatography/mass spectrometry (LC/
MS) at Climax Laboratories, Inc. (San Jose, CA). The LC/MS analysis
was conducted by using Shimazu 10 A HPLC system (Shimadzu
Scientiﬁc Instruments, Inc.) with ACE C18, 50  2.1 HPLC column
and ABSciex API-4000 Mass Spectrometer (ABSciex Corp) with
Electrospray Ionization (ESI) and negative Multiple ReactionMonitoring (MRM) Scan. A gradient elution was used in separating
the test compoundwith amobile phase A (0.1% formic acid in 5mM
of NH4AC) and B (0.1% formic acid in acetonitrile).
Scoring of cartilage degeneration, osteophyte formation, and
synovitis in mouse OA
Limbs were removed and knees decalciﬁed, parafﬁn-embedded,
and cut into 4-mm-thick sections and stained with Safranin-O.
Cartilage degeneration, osteophyte formation and synovitis scores
were calculated as previously described13. Scores for synovitis were
recorded for the femoral-medial and the tibial-medial condyles on
the operated side of the joint, and the scores for the two regions
were summed.
Stimulation of murine OA synovium
3 months after DMM induction, synovium was microdissected
from an additional group of untreated mice and roughly equal
pieces (matched by weight) were stimulated in triplicate with LPS
in the presence or absence of 140 ug/ml boswellic acid. Tissue was
lysed and levels of inﬂammatory cytokines were measured in su-
pernatants using a multiplex bead-based cytokine assay on the
Luminex platform (Millipore) or after extracting RNA for quanti-
tative PCR with results normalized to expression of gapdh
expression.
Statistical analysis
Cartilage degeneration, osteophyte formation, and synovitis
scores as well in vitro stimulation assays were analyzed with a two-
tailed unpaired t test to compare means of treatment groups. For
in vitro assays, minimal skew of triplicate results was conﬁrmed by
eye and for murine studies a Gaussian distribution was conﬁrmed
using the D’Agastino-Pearson normality test (GraphPad Prism.)
Data are presented as mean 95% conﬁdence intervals (CI).
Results
Levels of boswellic acid in plasma and synovium after oral or topical
administration
Table I demonstrates that topical administration resulted in
tissue levels of boswellic acid 2e6 times higher than plasma levels,
suggesting local absorption of boswellic acid rather than systemic
absorption with local recirculation and deposition. As expected,
topical administration resulted in lower plasma levels of boswellic
acid than did oral administration and the lipid-based topical
formulation (boswellic acid ointment) achieved signiﬁcantly higher
synovial levels than the aqueous topical formulation (boswellic
Q. Wang et al. / Osteoarthritis and Cartilage 22 (2014) 128e132130acid cream). Although the plasma levels of boswellic acid were only
slightly higher with the lipid-based formulation than with the
aqueous formulation, the synovial:plasma ratio (6.64:1.87) was
signiﬁcantly higher with the lipid-based formulation. Given the
observation that lipid-based boswellic acid ointment achieves
higher relative synovial tissue levels than boswellic acid cream, this
formulation was used as the topical comparator in the reported
murine treatment studies.Oral or topical boswellic acid attenuates mouse OA
At 12 weeks, we assessed the effect of the various treatments on
cartilage erosion, osteophyte formation, and synovitis. Analysis of
Safranin-O-stained tissues showed that both the oral and the
ointment preparation signiﬁcantly attenuated articular cartilage
erosion [Fig. 1(A)e(F)] with only a non-statistically signiﬁcant a
trend toward increased efﬁcacy in the oral treatment group
[Fig. 1(G)]. In addition, both the oral and ointment preparations
signiﬁcantly reduced knee synovitis and osteophyte formation
(P < 0.01 for each assessment, data not shown).Fig. 1. Oral or topical boswellic acid reduces cartilage erosion in a mouse model of OA. Mic
boswellic acid, or boswellic acid ointment for 12 weeks after surgery. (AeF) Representative
Scale bar: low-magniﬁcation (top) images, 500 mM; high-magniﬁcation (bottom) images, 12
topical boswellic acid ointment (n ¼ 8 mice per group). Data are shown as the mean þ 95%
experiments.Boswellic acid inhibits IL-1b and TLR4 induced synovial activation
Induction of synovial inﬂammation by several innate immune
ligands has been implicated in the pathogenesis of human and
murine OA14,15. Fig. 2(A) demonstrates a reduction in level of
several inﬂammatory cytokines in synovium of mice treated with
topical boswellic acid ointment compared with vehicle control
ointment. Using OA synovium from untreated mice, we demon-
strate the ability of boswellic acid to directly inhibit IL-1b induced
production of several inﬂammatory mediators from OA synovial
tissue at both the transcriptional [Fig. 2(B)] and protein level
[Fig. 2(C)]. Similarly, we conﬁrm the ability of boswellic acid to
inhibit TLR4 induced cytokine production from OA synovial tissue
after exposure to LPS [Fig. 2(D)].
Discussion
Current treatments for OA are purely symptomaticdthere are
no approved disease-modifying therapies. Moreover, most oral
medications are plagued by off-target effects and toxicities; in fact,
the most recent guidelines for the management of OA-associatede were surgically induced to develop OA via DMM, and then treated with vehicle, oral
Safranin-O-stained sections of the medial region of the mouse stiﬂe joints at 12 weeks.
5 mm. (G) Quantiﬁcation of cartilage loss in mice treated with vehicle ointment, oral, or
CI. **P < 0.01 by Student’s t-test. Results shown are representative of two independent
Fig. 2. Boswellic acid inhibits IL-1b and TLR4 induced cytokine production from OA synovium. Mice were surgically induced to develop OA via DMM and treated with topical
Boswellic acid ointment or vehicle control (n ¼ 3 mice per treatment group) and at 4 months, OA synovial tissue was microdissected and tissue lysates directly assayed for levels of
inﬂammatory cytokines (A). Alternatively, mice were surgically induced to develop OA and left untreated and at 4 months, OA synovial tissue was microdissected and stimulated
with IL-1b (B) or LPS (C, D) with or without Boswellic acid pre-treatment and levels of a panel of inﬂammatory mediators measured by quantitative PCR or by multiplex
immunoassay. All experiments were performed in triplicate. Data are shown as the mean þ 95% CI. *P < 0.05, **P < 0.01, ***P < 0.001 by unpaired t-test. LPS, lipopolysaccharide; IL,
interleukin; MCP, monocyte chemotactic protein; RANTES, regulated on activation normal T cell expressed and secreted; TNF, tumor necrosis factor; MMP, matrix metalloproteinase;
ADAMTs, a disintegrin and metalloproteinase with thrombospondin motifs; VEGF, vascular endothelial growth factor; COX, cyclooxygenase.
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possible for people over age 75 years3. In this study we assessed the
ability of both oral and topical boswellic acid to modify structural
progression in a post-traumatic model of OA.
We show that boswellic acid reduces cartilage loss, osteophyte
formation, and synovitis in this model and that topical adminis-
tration is similarly efﬁcacious to oral administration and provide
evidence to implicate inhibition of both IL-1b and TLR signaling as
potential mechanisms mediating this protective effect. Notably,
another well-studied mechanism by which boswellic acid may
inhibit inﬂammation is though inhibition of the 5-LO pathway.
Previous attempts to inhibit this pathway using have also demon-
strated the potential to provide disease modifying therapy for pa-
tients with OA16 including two proof-of-concept studies utilizing
orally administered derivatives of boswellic acid5,17.
Previous studies of topical NSAIDs, speciﬁcally topical diclofe-
nac, have shown that drugs can be delivered directly to the affected
joint, resulting in a greater drug concentration in synovial tissues
than in the blood2; we found that this was also the case with
topically administered boswellic acid. Although we cannot exclude
the possibility that boswellic acid is being locally concentrated in
the joint after systemic absorption, we believe that the demon-
stration of signiﬁcantly higher concentration of boswellic acid in
the joint tissue compared with the blood supports the hypothesis
that the compound is acting locally and is relatively restricted to the
targeted joint.Given the immunomodulatory functions of boswellic acid, our
ﬁndings suggest that boswellic acid has potential as a novel, tar-
geted, anti-inﬂammatory therapy that attenuates joint damage in
OA. The most well-described mechanism of action ascribed to
boswellic acid is inhibition of the 5-LO pathway7. This pathway
involves the conversion of arachidonic acid to leukotrienes,
including LTB. Levels of LTB4 are abnormally high in OA synovial
ﬂuid, and animal studies suggest that LTB4 has a critical role in OA.
In addition to preventing LTB4-induced cytokine production,
boswellic acid has been suggested to inhibit cytokine mediated
cartilage loss11 TLR4-mediated cytokine production in human
monocytes9. Given the role of the innate immune system14,
including speciﬁc endogenous TLR agonists, in driving OA-
associated inﬂammation18, our data suggest that cytokine and/or
TLR4 inhibition may be another mechanism by which boswellic
acid exerts its protective effects and further identiﬁes the TLR4
pathway as a potential target for disease modifying anti-osteoar-
thritis drug (DMOAD) therapy.
One limitation of this study is the administration of a Boswellia
serrata extract. Though the major component of this extract is
Boswellic acids, the presence of other undeﬁned molecules could
also contribute to the therapeutic efﬁcacy observed in this study and
thus future studies will beneﬁt from use of a more pure formulation
of speciﬁc Boswellic acids both to conﬁrm efﬁcacy and to provide a
regulatory path for human trials. Another limitation is the use of
a mouse model of traumatic OA in which disease is induced in a
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joint injury. However, despite the inherent limitation of such
controlled animal experiments, the DMM model appears highly
relevant to human OA as demonstrated by both histopathologic and
mechanistic similarities12. Similarly, our ex vivo studies utilize a
non-physiologic TLR4 agonist, bacterial LPS. However, our parallel
studies have obtained similar results using endogenous TLR4
ligands previously identiﬁed from RA and OA synovial ﬂuid (data
not shown). Another limitation of this study is the observation that,
despite higher levels of boswellic acid in synovium from mice
treated with topical therapy compared with oral therapy, disease
was abrogated to a greater degree in the orally treatedmice. Though
we have no clear explanation for this observation, it is possible
that there are unmeasured metabolites after or administration. We
hypothesize that although topical therapy may suppress synovial
inﬂammation, oral therapy may better inhibit intra-articular and
cartilaginous inﬂammation due to its wider availability.
Given the overall safety of Boswellia and its boswellic acid de-
rivatives in small clinical studies in individuals with OA, and a
presumed decrement in risk with topical therapy, boswellic acid
could potentially be used for the prolonged durations likely required
to prevent and/or abrogate the progression of post-traumatic knee
OA. Human studies of oral and topical boswellic acid are needed to
better deﬁne the pharmacokinetics properties and, ultimately,
evaluate the safety and therapeutic efﬁcacy in both the treatment of
pain and prevention of structural progression in human OA.
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